Brexafemme Approved For Recurrent Yeast InfectionsDecember 6, 2022The Food and Drug Administration (FDA) has approved Brexafemme for a second indication for reduction in incidence of recurrent vulvovaginal candidiasis, Scynexis announced Thursday “Brexafemme was already the…
FDA announces Project OrbisOctober 1, 2019The U.S. Food and Drug Administration (FDA) has announced Project Orbis, a new initiative from the FDA Oncology Center of Excellence (OCE), which will provide “a framework for…
